What type of study is this?

This is a In Vitro Study study (also classified as: Animal Study).

September 24, 2025Open Access

ILC3 inhibits Osteoclastogenesis and ameliorates Inflammatory Bone Loss in Post-menopausal Osteoporosis

View Full Paper

Ask AI

Bookmark

Authors

ABAsha Bhardwaj LSLeena Sapra SKSimran Kaur

Discussion

Member takes

Overview

In vitro analysis shows ILC3 inhibits osteoclastogenesis, while dysregulated ILC3 contributes to inflammatory bone loss in postmenopausal osteoporosis.

Key Points

ILC3 effectively inhibits osteoclastogenesis, showing promise in managing inflammatory bone loss related to postmenopausal osteoporosis.
In a mouse model, ILC3 frequency changes are linked to the progression of bone loss, revealing significant implications for osteoporosis treatment.
Dysbiosis alters ILC3 dynamics, increasing certain ILC3 subsets, like T-bet+ ILC3, highlighting a new target for immunotherapy.
This study's findings suggest that manipulating ILC3 could provide novel approaches for treating postmenopausal osteoporosis.

Cite This Study

Bhardwaj et al. (2025) studied this question.

synapsesocial.com/papers/68d6e16f8b2b6861e4c3fe53 https://doi.org/10.1101/2025.09.20.677486

View Full Paper

Ask AI

Bookmark

September 24, 2025Open Access

ILC3 inhibits Osteoclastogenesis and ameliorates Inflammatory Bone Loss in Post-menopausal Osteoporosis

View Full Paper

Ask AI

Bookmark

Authors

ABAsha Bhardwaj LSLeena Sapra SKSimran Kaur

Discussion

Member takes

Overview

In vitro analysis shows ILC3 inhibits osteoclastogenesis, while dysregulated ILC3 contributes to inflammatory bone loss in postmenopausal osteoporosis.

Key Points

ILC3 effectively inhibits osteoclastogenesis, showing promise in managing inflammatory bone loss related to postmenopausal osteoporosis.
In a mouse model, ILC3 frequency changes are linked to the progression of bone loss, revealing significant implications for osteoporosis treatment.
Dysbiosis alters ILC3 dynamics, increasing certain ILC3 subsets, like T-bet+ ILC3, highlighting a new target for immunotherapy.
This study's findings suggest that manipulating ILC3 could provide novel approaches for treating postmenopausal osteoporosis.

Cite This Study

Bhardwaj et al. (2025) studied this question.

synapsesocial.com/papers/68d6e16f8b2b6861e4c3fe53 https://doi.org/10.1101/2025.09.20.677486

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark